LOXL2—A New Target in Antifibrogenic Therapy?

The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated. Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and/or by promoting its resolution. Therefore, the study of the molecular mechanisms involved in the pathogenesis of liver fibrosis is critical for the development of future antifibrotic therapies. The fibrogenesis process, common to all forms of liver injury, is characterized by the increased deposition of extracellular matrix components (EMCs), including collagen, proteoglycans, and glycoproteins (laminin and fibronectin 2). These changes in the composition of the extracellular matrix components alter their interaction with cell adhesion molecules, influencing the modulation of cell functions (growth, migration, and gene expression). Hepatic stellate cells and Kupffer cells (liver macrophages) are the key fibrogenic effectors. The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action. The research of biochemical changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix. LOXL2 inhibition can decrease cell numbers, proliferation, colony formations, and cell growth, and it can induce cell cycle arrest and increase apoptosis. The development of a new humanized IgG4 monoclonal antibody against LOXL2 could open the window of a new antifibrogenic treatment. The current therapeutic target in patients with liver cirrhosis should focus (after the eradication of the causal agent) on the development of new antifibrogenic drugs. The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure.

[1]  M. Manns,et al.  Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease , 2019, Hepatology.

[2]  J. Chan,et al.  Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension , 2018, Hepatology.

[3]  M. Karsdal,et al.  Assessment of liver fibrosis progression and regression by a serological collagen turnover profile. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[4]  D. Rockey,et al.  Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. , 2018, Gastroenterology.

[5]  J. Ladero,et al.  Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[6]  Z. Goodman,et al.  The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial , 2017, Hepatology.

[7]  X. Forns,et al.  Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. , 2017, Gastroenterology.

[8]  L. Valenti,et al.  Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. , 2017, Clinical science.

[9]  Y. Ilan,et al.  Potential use of metabolic breath tests to assess liver disease and prognosis: has the time arrived for routine use in the clinic? , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[10]  A. Benson,et al.  A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma , 2017, The oncologist.

[11]  A. Benson,et al.  A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma , 2017, The oncologist.

[12]  D. Schuppan,et al.  Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal , 2017, Gut.

[13]  H. Collard,et al.  Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. , 2017, The Lancet. Respiratory medicine.

[14]  Richard Moreau,et al.  Liver sinusoidal endothelial cells: Physiology and role in liver diseases. , 2017, Journal of hepatology.

[15]  J. Crespo,et al.  Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. , 2017, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[16]  Asociacion Latinoamericana para el Estudio del Higado EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[17]  I. Ruiz-Trillo,et al.  Origin and evolution of lysyl oxidases , 2015, Scientific Reports.

[18]  J. Bosch,et al.  Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. , 2015, Journal of hepatology.

[19]  C. Trautwein,et al.  Hepatic fibrosis: Concept to treatment. , 2015, Journal of hepatology.

[20]  S. Friedman,et al.  Pathobiology of liver fibrosis: a translational success story , 2015, Gut.

[21]  I. Ng,et al.  Lysyl oxidase‐like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma , 2014, Hepatology.

[22]  F. Tacke,et al.  Roles for chemokines in liver disease. , 2014, Gastroenterology.

[23]  R. Ehman,et al.  Role of magnetic resonance elastography in compensated and decompensated liver disease. , 2014, Journal of hepatology.

[24]  Frank Tacke,et al.  Macrophage heterogeneity in liver injury and fibrosis. , 2014, Journal of hepatology.

[25]  J. Fallowfield,et al.  Liver fibrosis and repair: immune regulation of wound healing in a solid organ , 2014, Nature Reviews Immunology.

[26]  M. Robson,et al.  Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease , 2014, Journal of hepatology.

[27]  Lan Wei,et al.  Molecular MRI of collagen to diagnose and stage liver fibrosis. , 2013, Journal of hepatology.

[28]  N. Kaminski,et al.  Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression , 2013, European Respiratory Journal.

[29]  V. Paradis,et al.  The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. , 2013, Journal of hepatology.

[30]  D. Schuppan,et al.  Evolving therapies for liver fibrosis. , 2013, The Journal of clinical investigation.

[31]  D. Rockey Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  M. Manns,et al.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.

[33]  J. Fallowfield,et al.  Edinburgh Research Explorer Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis Differential Ly-6C expression identi fi es the recruited macrophage phenotype, which orchestrates the regression of murine liver fi brosis , 2022 .

[34]  K. Iwaisako,et al.  Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. , 2012, Gastroenterology.

[35]  A. Waisman,et al.  Th17 cells regulate liver fibrosis by targeting multiple cell types: many birds with one stone. , 2012, Gastroenterology.

[36]  Laurent Castera,et al.  Noninvasive methods to assess liver disease in patients with hepatitis B or C. , 2012, Gastroenterology.

[37]  B. Hinz,et al.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. , 2012, The American journal of pathology.

[38]  T. Luedde,et al.  Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury , 2011, Gut.

[39]  T. Wynn,et al.  Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[40]  S. Friedman,et al.  Pathogenesis of liver fibrosis. , 2011, Annual review of pathology.

[41]  Derek Marshall,et al.  Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment , 2010, Nature Medicine.

[42]  Scott L. Friedman,et al.  Evolving challenges in hepatic fibrosis , 2010, Nature Reviews Gastroenterology &Hepatology.

[43]  J. Dranoff,et al.  Portal fibroblasts: Underappreciated mediators of biliary fibrosis , 2010, Hepatology.

[44]  T. Wynn,et al.  Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent , 2010, The Journal of experimental medicine.

[45]  F. Marra,et al.  Mononuclear cells in liver fibrosis , 2009, Seminars in Immunopathology.

[46]  Jaume Bosch,et al.  Angiogenesis in liver disease. , 2009, Journal of hepatology.

[47]  O. Pappo,et al.  A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT , 2008, Journal of viral hepatitis.

[48]  Yosuke Osawa,et al.  TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.

[49]  F. Marra,et al.  Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. , 2007, The American journal of pathology.

[50]  H. Kagan,et al.  Lysyl oxidase: an oxidative enzyme and effector of cell function , 2006, Cellular and Molecular Life Sciences CMLS.

[51]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[52]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[53]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[54]  J. Fallowfield,et al.  Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. , 2004, Gastroenterology.

[55]  D. Rockey Vascular mediators in the injured liver , 2003, Hepatology.

[56]  T. Roskams,et al.  Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. , 2001, Journal of hepatology.

[57]  J. Iredale,et al.  Pathogenesis of liver fibrosis. , 1997, Clinical science.